Here, we aim to explore CD133‐positive circulating tumor cells (CTCs) in stage I patients of NSCLC to predict pathological high‐risk factors of patients, thereby aiding clinical decision‐making. The gene discussed is PROM1; the disease is non-small cell lung carcinoma.